Dr. Arthur Winer, MD
Claim this profileInova Schar Cancer Institute
Studies Fibrosis
Studies Hepatocellular Carcinoma
4 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Arthur Winer, MD is currently running
Memantine
for Liver Cancer
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
Recruiting1 award Phase 2 & 3
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
More about Arthur Winer, MD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Arthur Winer, MD has experience with
- Nab-paclitaxel
- Gemcitabine
- Memantine
- Cisplatin
- Yittrium-90
- Liposomal Irinotecan
Breakdown of trials Arthur Winer, MD has run
Fibrosis
Hepatocellular Carcinoma
Liver Cancer
Liver Cirrhosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Arthur Winer, MD specialize in?
Arthur Winer, MD focuses on Fibrosis and Hepatocellular Carcinoma. In particular, much of their work with Fibrosis has involved Stage III patients, or patients who are undergoing treatment.
Is Arthur Winer, MD currently recruiting for clinical trials?
Yes, Arthur Winer, MD is currently recruiting for 3 clinical trials in Fairfax Virginia. If you're interested in participating, you should apply.
Are there any treatments that Arthur Winer, MD has studied deeply?
Yes, Arthur Winer, MD has studied treatments such as Nab-paclitaxel, Gemcitabine, Memantine.
What is the best way to schedule an appointment with Arthur Winer, MD?
Apply for one of the trials that Arthur Winer, MD is conducting.
What is the office address of Arthur Winer, MD?
The office of Arthur Winer, MD is located at: Inova Schar Cancer Institute, Fairfax, Virginia 22031 United States. This is the address for their practice at the Inova Schar Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.